Skip to main content

The RiBVD Regimen Offers a High Complete Response Rate in Elderly Patients with Untreated Mantle- Cell Lymphoma. Preliminary Results of the LYSA Trial “Lymphome Du Manteau 2010 SA”

Conference Correspondent - Conference Highlights ASH

Supported by the French LYSA (Lymphome Du Manteau 2010 SA) group, this prospective phase 2 trial evaluated the efficacy and safety of a 4-drug combination known as RiBVD (rituximab, bendamustine, bortezomib, and dexamethasone) in elderly patients with previously untreated mantle- cell lymphoma (MCL), including patients older than 65 years or patients who were not eligible for autologous stem-cell transplantation.  

Qualifying patients received a total of 6 cycles of the RiBVD regimen if they responded after 4 cycles. The regimen was administered every 4 weeks. Primary prophylaxis with acyclovir was mandatory for herpes virus reactivation; no antibiotics were recommended for bacterial prophylaxis. Gressin and colleagues presented preliminary analysis of the RiBVD regimen after 4 cycles of treatment.

Of the 76 patients enrolled, 70 patients were evaluated. The patients’ median age was 72 years. Most patients were male with advanced stage MCL and a good performance status. In addition, the MIPI (Mantle-Cell Lymphoma International Prognostic Index) scores indicated mostly intermediate- and high-risk disease.

Among the 70 evaluable patients, the overall response rate was 87%, including 60% of patients who achieved complete response (CR) or CR unconfirmed. Of the 61 patients who received a PET (positron emission tomography) scan after 4 cycles, 64% achieved CR. Overall, 3 patients experienced disease progression.

The adverse events (AEs) associated with RiBVD included grade 3 or 4 neutropenia (21%), grade 3 or 4 thrombocytopenia (15%), and grade 3 or 4 anemia (2%). Nonhematologic AEs reported in more than 10% of cycles included fatigue; allergic reactions; fever without neutropenia; neuropathy; weight loss; cutaneous rash; gastrointestinal symptoms; and elevated transaminase levels, creatinine levels, and glucose levels. Serious AEs included 4 deaths: 1 patient died of pneumonia, 2 patients died of cardiac arrest, and 1 patient died of progressive multifocal leukoencephalopathy. Other serious AEs included 12 infections (ie, pneumonia, herpes zoster, listeriosis). In addition, 4 incidences of febrile neutropenia and 3 incidences of cutaneous hypersensitivity reactions were reported.

Overall, the safety profile of RiBVD appears acceptable and manageable. This interim analysis demonstrates the efficacy of 4 cycles of RiBVD in patients with untreated MCL. The high overall response rate has been shown to be predictive of a long duration of response.  

Gressin R, Callanan M, Daguindau N, et al. The RiBVD regimen (rituximab IV, bendamustine IV, velcade SC, dexamethasone IV) offers a high complete response rate in elderly patients with untreated mantle cell lymphoma. Preliminary results of the LYSA trial “Lymphome Du Manteau 2010 SA”. Blood. 2013;122. Abstract 370.

Related Items
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology published on February 25, 2020 in Conference Highlights ASH
Improving the Standard of Care
R. Donald Harvey, PharmD, FCCP, BCOP
Videos published on January 5, 2016 in Conference Highlights ASH
Real-World Data on Primary Treatment for Mantle-Cell Lymphoma 2000-2011 – A Nordic Lymphoma Group Observational Study
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Oral Arsenic Trioxide-Based Regimen as Salvage Treatment for Relapsed or Refractory Mantle-Cell Lymphoma
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma in Need of Palliative Therapy
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Last modified: August 30, 2021